GlobeNewsWire
13 Aug 2026, 05:00 UTC · 2h ago
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
13 Aug 2026, 05:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Regulatory decisions for the LB6V Lyme disease vaccine candidate are expected within the next twelve months. — As the only late-stage candidate for a massive addressable market (280m+ people), approval would be a transformative catalyst for the company's valuation.
+0.80Phase 2 results for the S4V2 Shigella vaccine candidate are expected in the third quarter of 2026. — Positive results for a WHO-priority vaccine with a $500m+ annual market opportunity would provide a secondary growth pillar.
+0.50First-half 2026 revenues were €65.8 million, a decrease from €97.6 million in the same period previously. — A significant sequential decline in revenue indicates weakening current commercial performance despite the pipeline potential.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Valneva reaffirmed its financial guidance for 2026 and maintains a strong cash position following April financing. — Stability in guidance and liquidity reduces immediate bankruptcy or dilution risk, providing a steady floor for the stock.
+0.30Which stocks this story touches
The company reaffirmed financial guidance, maintained a strong cash position, and has several advanced vaccine candidates with positive regulatory pathways.
Pfizer has expressed optimism regarding the regulatory approval prospects for the co-developed Lyme disease vaccine candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
MarketBeat
1h ago
